

1 **RESEARCH ARTICLE**

2 **Global seasonal activities of respiratory syncytial virus before the COVID-19 pandemic:**
3 **a systematic review**

4 Songwei Shan^{1,2}, Weixin Zhang¹, Huizhi Gao¹, Pei-Yu Huang¹, Zhanwei Du^{1,2}, Yuan Bai^{1,2},
5 Yiu-Chung Lau^{1,2}, Dongxuan Chen^{1,2}, Eric HY Lau^{1,2}, Joshua Nealon¹, Peng Wu^{1,2}

6

7 ¹World Health Organization Collaborating Centre for Infectious Disease Epidemiology and
8 Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong
9 Kong, Hong Kong SAR, China.

10 ²Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong
11 Kong SAR, China.

12

13

14 Corresponding author: Peng Wu, School of Public Health, The University of Hong Kong,
15 email: pengwu@hku.hk, Tel: 3917 6746

16

17 Running head: Global RSV seasonality

18

19 Word count (Abstract): 248

20 Word count (main text): 3,356

21 Keywords: activity, respiratory syncytial virus, seasonality, global

22 **ABSTRACT**

23 **Background:** Varied seasonal patterns of respiratory syncytial virus (RSV) have been
24 reported worldwide. We aimed to review the patterns of RSV activity globally before the
25 COVID-19 pandemic and to explore factors potentially associated with RSV seasonality.

26 **Methods:** We conducted a systematic review on articles identified in PubMed reporting RSV
27 seasonality based on data collected before 1 January 2020. Information on the timing of the
28 start, peak, and end of an RSV season, study location, study period, and details in study
29 methods were extracted. RSV seasonal patterns were examined by geographic location,
30 calendar month, analytic method and meteorological factors including temperature and
31 absolute humidity. Correlation and regression analyses were conducted to explore the
32 relationship between RSV seasonality and study methods and characteristics of study
33 locations.

34 **Results:** RSV seasons were reported in 209 articles published in 1973-2023 for 317 locations
35 in 77 countries. Variations were identified in types of data, data collection and analytical
36 methods across the studies. Regular RSV seasons were similarly reported in countries in
37 temperate regions, with highly variable seasons identified in subtropical and tropical
38 countries. Durations of RSV seasons were relatively longer in subtropical and tropical
39 regions than from temperate regions. Longer durations of RSV seasons were associated with
40 a higher daily average mean temperature and daily average mean absolute humidity.

41 **Conclusions:** The global seasonal patterns of RSV provided important information for
42 optimizing interventions against RSV infection. Heterogeneity in study methods highlighted
43 the importance of developing and applying standardized approaches in RSV surveillance and
44 data reporting.

45 INTRODUCTION

46 Respiratory syncytial virus (RSV) is a leading cause of hospitalization for acute lower
47 respiratory tract infection (LRTI) in young children less than 5 years old ¹⁻³, as well as an
48 increasingly recognized important pathogen in older adults (aged ≥ 65) ^{4,5}. Globally, RSV
49 was estimated to cause nearly 25 million LRTI episodes and more than 70,000 deaths every
50 year ⁶. In addition to Palivizumab, a monoclonal antibody recommended for high-risk infants
51 ^{7,8} providing a short-term protection against RSV-associated severe infections ^{9,10}, a new
52 monoclonal antibody nirsevimab with a prolonged protection ^{11,12} has been approved by the
53 EU and the UK ¹³. Recently the first RSV vaccine (Arexvy, RSVPreF3 from GSK) approved
54 for the use in older adults and several other vaccine candidates in their final stage of testing
55 demonstrated promising efficacy in preventing RSV-associated LRTI and severe infections
56 ^{14,15}.

57

58 Activities of RSV varied temporally and geographically. In temperate regions, the highest
59 viral activities have been observed during winter months ^{16,17} with similar intensities across
60 different years. Two-year cycles of RSV activity have been reported for some countries in
61 Northern Europe, with a major epidemic wave in winter followed by a minor one in spring
62 next year ¹⁸. In subtropical and tropical regions, seasonal patterns of RSV were more diverse
63 and less clear than those reported for temperate countries ¹⁹. Knowledge about the seasonality
64 of RSV, can guide the formulation of prevention strategies and the planning of public health
65 resources. In particular, accurate estimates of the RSV season start and its duration can help
66 to determine the optimal timing of initial doses and optimal dosing interval for prophylactic
67 monoclonal antibodies and vaccination schedules.

68

69 We conducted a systematic review on RSV seasonality to characterize the global patterns of
70 RSV activity by summarizing the reported start, peak and end of RSV seasons worldwide and
71 describe approaches applied in analyzing the seasonality. We aimed to provide a better
72 understanding of the seasonal patterns of RSV circulation to inform policy and decisions in
73 prevention, diagnosis, and treatment of RSV infections.

74

75 **METHODS**

76 *Literature search strategy and selection criteria*

77 This systematic review was conducted following the Preferred Reporting Items for
78 Systematic Reviews and Meta-Analyses (PRISMA) guidelines²⁰. We focused on studies in
79 which seasonal patterns of RSV were characterized by providing the time of the start, peak
80 and/or end of a season based on laboratory-confirmed RSV infection data. We searched
81 published articles from PubMed on January 17, 2023 using the combination of following
82 search items (*1 and 2*) in “Title/Abstract” (Figure 1):

- 83 1. “RSV” or “Respiratory Syncytial Virus”
- 84 2. “seasonality” or “season*”

85

86 Two authors (S.S. and W.Z.) performed the literature search (#1 and #2) and screened
87 retrieved articles independently. Full-text screening was conducted after title/abstract
88 screening. Two authors (S.S. and W.Z.) independently identified articles for inclusion. Any
89 disagreement in article selection and data retrieval was resolved by a third author (P.W.).

90

91 Eligible articles were studies reporting the seasonality of RSV based on monthly or weekly
92 laboratory-confirmed RSV infections collected for a specified place, i.e., a city, a province or
93 a country, for three years or longer. We excluded articles if: 1) the full text was not available

94 or not in English, 2) the analysis was based on less than three years' data, 3) the average
95 number of reported RSV infections per year in a study was less than 50, 4) the time of the
96 start, peak and/or end of RSV seasons was not specified in a calendar month or week. If an
97 investigation on RSV seasonality covered the time period beyond 2019, the study period
98 before the COVID-19 pandemic ≥ 3 years would be included in our analysis, and the RSV
99 data collected during the pandemic would be excluded. Articles without original data analysis
100 on RSV activities, such as reviews, commentaries, letters, were excluded, but we reviewed
101 the references of these articles for additional studies to include for screening.

102

103 *Data extraction and analysis*

104 Two authors (S.S. and W.Z.) independently extracted data into a standardized data extraction
105 form. Data fields included the timing (start, peak, and end) of an RSV season, study location
106 (city, region or country), study period, information on study characteristics (such as the
107 source of cases, case definitions, laboratory testing methods and analytic methods applied to
108 determine RSV seasons). We classified the sources of study cases into outpatient, inpatient,
109 outpatient and inpatient, case definitions into influenza-like-illness (ILI) or acute respiratory
110 infection (ARI), severe acute respiratory infection (SARI) and acute LRTI and grouped
111 laboratory testing methods for RSV confirmation into virus detection, antibody detection,
112 antigen detection, and nucleic acid detection.

113

114 One publication might contain several different investigations on seasonal patterns of RSV,
115 either based on different data sources, or based on the same dataset but with different analytic
116 methods. If more than one estimate on timing of RSV season was reported in a single
117 publication, using different data sources or methods, all were extracted and included in our
118 analyses. It was common that one investigation on RSV seasonality was conducted based on

119 more than one type of case source, case definition and/or testing method, and all the
120 methodological details were extracted and documented for analyses. Analytic methods used
121 by different studies to determine the RSV seasons were classified as qualitative methods and
122 quantitative methods based on whether the analysis on RSV seasonality was carried out using
123 a statistical or mathematical approach, and the quantitative methods were further divided into
124 three groups, threshold-based, coverage-based and model-based (*Supplementary Materials*).

125

126 In addition to the study-specific information, we also documented the latitude, daily average
127 mean temperature and daily average mean relative humidity for all study locations reported in
128 each investigation using Google Geocoding API ²¹ and R package GSOR ²²(Supplementary
129 materials). The extracted daily average mean temperature and relative humidity data were
130 used to derive the daily average mean absolute humidity for each location. We also extracted
131 the geoclimatic information of each study site, and classified the investigations of RSV
132 seasonality into three groups based on the latitude of the study sites, temperate zone (latitude >
133 35° or latitude < -35°), subtropical zone (23.5° < latitude ≤ 35° or -35° ≤ latitude < -23.5°)
134 and tropical zone (-23.5° ≤ latitude ≤ 23.5°).

135

136 We described the reported RSV seasons as a function of geographical location,
137 meteorological factors and characteristics of study design, and explored potential associations
138 using Pearson correlation analyses and Kendall's rank correlation between the duration of the
139 season and the latitude, daily average mean temperature and daily average mean absolute
140 humidity of study sites as well as the analytic method and climate zone. Finally, linear
141 regression models were applied to explore the independent associations between the duration
142 of RSV seasons and the abovementioned factors as covariates. The statistical analyses were

143 conducted using R software Version 4.0.3 (R Foundation for Statistical Computing, Vienna,
144 Austria).

145

146 **RESULTS**

147 We identified 2,510 citations from the PubMed through the keyword search and additional 19
148 citations from other sources. In total, 209 publications were included after screening based on
149 the inclusion and exclusion criteria (Figure 1) and 552 investigations of RSV seasonality
150 were identified and included in analyses.

151

152 The identified studies were published between 1973 and 2023, with the majority (147/209,
153 70%) from 2010 onwards (Supplementary Figure 1). RSV seasonality was reported for 317
154 distinct study sites in 77 countries from Asia, Europe, North America, South America,
155 Oceania and Africa (Figure 2). Most investigations (342/552, 62%) were conducted with a
156 study period of 3-6 years (Supplementary Figure 1), with the longest one from Malaysia
157 using surveillance data over 27 years²³. Among the identified publications, more than half
158 (124/209, 59%) were from temperate regions (latitude > 35° or latitude < -35°), followed by
159 31% (65/209) and 22% (47/209) in subtropical (23.5° < latitude ≤ 35° or -35° ≤ latitude < -
160 23.5°) and tropical (-23.5° ≤ latitude ≤ 23.5°) regions, respectively (Table 1, Supplementary
161 Table 1).

162

163 The information on the case source, case definition, and laboratory testing methods was
164 missing in some investigations (case source: 260/552, 47%; case definition: 310/552, 56%;
165 testing method: 127/552, 23%). Among those with information of case source and case
166 definition provided, the majority of investigations (152/292, 52%) identified RSV cases from
167 inpatients, and ARI or ILI (150/242, 62%) was the most frequently used syndromic

168 definitions to screen patients for RSV testing, and antigen (325/552, 59%) and nucleic acid
169 detections (323/552, 59%) were the most commonly used laboratory testing methods in more
170 recent publications (Table 1, Supplementary Table 1, Supplementary Figures 2-3). The
171 majority of investigations (373/552, 68%) applied quantitative methods to determine the time
172 of the start, peak and/or end of seasons, and among these studies, over half of the
173 investigations used the threshold-based method (205/373, 55%) (Supplementary Tables 2-3).

174

175 The majority of the investigations were conducted using data collected from locations in the
176 Northern Hemisphere (NH) and indicated one RSV season every year (Figure 2). A small
177 number of investigations (11/552, 2%) reported two RSV peaks identified in one year
178 (Supplementary Table 4) while 18 (3%) investigations indicated unique RSV seasonal
179 patterns repeated every 2 years (Supplementary Table 5). Among study sites reporting one
180 RSV season annually, locations in temperate countries were fairly consistent in the time of
181 the start, peak and end of RSV seasons in either the NH or Southern Hemisphere (SH)
182 (Figure 3). In temperate countries, RSV activities generally started from late autumn or early
183 winter, i.e., October-December in NH, May-June in SH, peaked in winter (December-
184 February in NH, and June to July in SH), and ended in late winter or spring (February-May in
185 NH, and July-September in SH). (Figure 3, Supplementary Figure 4). Larger variations were
186 observed in the start, peak and end month of RSV seasons in subtropical and tropical
187 countries at a lower latitude, with high RSV activities observed in July/August-November in
188 tropical locations (Supplementary Figures 5-6). The durations of RSV seasons were relatively
189 shorter in study sites in the temperate region (median: 3.97 months, interquartile range (IQR):
190 3.00-5.00) compared with the estimates from subtropical (4.00, 3.52-6.14) and tropical
191 countries (5.00, 4.00-6.00) (Figure 2, Supplementary Figure 6).

192

193 The Pearson correlation analysis indicated an overall negative association between the
194 duration of the RSV season (in months) and the latitude both in the NH ($p < 0.001$) and the SH
195 ($p = 0.002$) (Supplementary Table 7), and the statistical significance in the association was
196 only indicated with the estimates derived from quantitative methods ($p < 0.001$). Positive
197 associations were indicated in the correlation analyses between the daily average mean
198 temperature (correlation coefficient: 0.33; 95% CI: 0.22, 0.44) and absolute humidity (0.34;
199 0.22, 0.45) of the study locations and the durations of RSV season estimated by the
200 quantitative methods ($p < 0.001$) but not for those estimated by the qualitative methods
201 (Supplementary Table 7). Durations of RSV seasons appeared to be longer in tropical
202 /subtropical regions than the estimates from temperate regions, and the estimated RSV
203 seasons were longer from the threshold-based methods, but shorter from the coverage-based
204 method (Table 2, Supplementary Table 8).

205

206 In the main analysis with the linear regression model, we identified that climatic zone
207 appeared to be independently associated with the estimated duration of RSV seasons, and
208 analytic method used in estimating RSV seasons, annual daily average mean absolute
209 humidity at the study location could also explain some variations (Adjusted $R^2 = 0.33$ for
210 estimates from quantitative approaches, 0.25 for all estimates) in the estimated durations of
211 RSV seasons (Table 2, Supplementary Table 8). Considering the close intercorrelations
212 between climatic zone, latitude and temperature, we included the climatic zone (Table 2,
213 Supplementary Table 8), latitude (Supplementary Tables 9-10) and daily average mean
214 temperature (Supplementary Tables 11-12) of study locations into different linear regression
215 models separately. The duration of RSV season would decrease by 0.041 (95% CI: 0.017,
216 0.064) months with every increase of 1 degree in latitude, and increase by 0.058 (95% CI:
217 0.0077, 0.11) months with every increase of 1 degree in daily average mean temperature.

218 Durations of RSV seasons estimated for the subtropical and tropical locations were on
219 average 1.06 (95% CI: 0.45, 1.66) and 1.65 (95% CI: 0.77, 2.54) months longer than for the
220 study sites in the temperate region. Compared to the coverage-based methods, the threshold-
221 based methods tended to produce longer estimates of the duration of RSV season by 1.43 (95%
222 CI: 0.96, 1.90) months. Overall, the duration of RSV season prolonged by 0.013 (95% CI: -
223 0.0048, 0.030) months with every 1 g/m³ increase in absolute humidity at the study location
224 (Table 2).

225

226 **DISCUSSION**

227 RSV seasonal patterns have been studied widely in particular since the last decade, with most
228 of the data reported from temperate countries in the Northern Hemisphere. Our review
229 indicated that largely similar seasonal patterns of RSV were observed in locations from the
230 same climatic region either in the NH or the SH. In temperate regions, RSV activities
231 primarily showed regular annual patterns starting in winter seasons, and the estimated
232 durations of RSV season were relatively shorter than the reported from tropical and
233 subtropical regions where prolonged RSV circulations were often more than half a year with
234 greatly varied times of season start and/or peak.

235

236 Human infections of RSV are likely driven by two major antigenic groups, A and B ²⁴
237 between which cross-immunity has been suggested ^{25,26}. However, RSV typing is often not
238 included in most of the established surveillance systems ²⁷. The increasing susceptibility in
239 infants due to the loss of protection from waning maternal antibodies leads to a higher risk of
240 infection particularly in young children with high-risk conditions ^{1,28,29}, potentially driving
241 the transmission of RSV in the population ³⁰ although the virus can infect people at any age
242 including older adults ^{31,32}. RSV shows comparable environmental survivability and

243 transmissibility to influenza viruses with a similar estimate of the basic reproduction number
244 (R_0) and household second attack rate³³. Increasing RSV activities were commonly reported
245 in cold seasons starting from late autumn through to early spring in temperate regions, and in
246 rainy seasons in tropical/subtropical areas, and the associations between RSV activities and
247 environmental factors including temperature, relative/absolute humidity, rainfall were
248 inconsistently reported from studies conducted in tropical areas³⁴⁻³⁶.

249

250 RSV seasonality characterised in different studies appeared to be associated with the
251 approaches used in data collection and analysis¹⁹. Previous research demonstrated that the
252 timing of RSV seasons determined with laboratory surveillance data might be different from
253 the results based on hospitalized patient data although the two estimates were highly
254 correlated³⁷. The improvement of laboratory testing methods could also affect the estimates
255 of RSV seasons^{38,39}. Our review showed that estimates of the timing of RSV seasons were
256 correlated with the analytic approaches used in the studies, with shorter durations of RSV
257 seasons estimated from “coverage-based method” (defined as the shortest time period when
258 the majority of confirmed (severe) RSV infections occurred) than the estimates from the
259 threshold-based methods which although were highly dependent on the often arbitrarily
260 selected threshold of varied measures for RSV activities, such as proportion of virus
261 detections or patients presenting ILI/ARI symptoms⁴⁰. Therefore, prudent comparison and
262 interpretation of RSV seasons estimated from different studies or with different approaches is
263 necessary.

264

265 RSV surveillance is often established based on the existing routine surveillance on influenza,
266 more commonly seen in developed economies including the US⁴¹, Canada⁴² and some
267 European countries⁴³. The WHO initiated a pilot RSV surveillance scheme by leveraging the

268 current Global Influenza Surveillance and Response System covering over 100 countries to
269 explore possible surveillance strategies including case definitions, laboratory methods and
270 target population, etc.⁴⁴. Current RSV surveillance largely applied similar syndromic case
271 definitions as those used for influenza surveillance, i.e., sampling patients showing influenza-
272 like-illness and testing for the virus, while the validity of using such case definitions for RSV
273 surveillance has been questioned⁴⁵. In some countries/areas RSV surveillance was not
274 conducted throughout a year but only during restricted period(s) following the influenza
275 surveillance protocol given the regular annual influenza seasons in those locations^{17,46}.
276 However, this might lead to an underreporting of RSV infections during the non-surveillance
277 periods⁴⁷.

278

279 During the COVID-19 pandemic, circulation of respiratory viruses including RSV changed
280 considerably worldwide largely due to implementation of non-pharmaceutical interventions
281 and changes in human behaviours in response to the pandemic^{48,49}. RSV remained at a low
282 level in many countries in 2020 when public health and social measure were widely adopted
283 globally to contain the spread of SARS-CoV-2, but caused surges of infections with a large
284 number of severe cases admitted into hospital in some countries when some interventions
285 were relaxed from 2021 onwards^{50,51}, including the US during 2021-2023⁵², some
286 geographically separated locations in Australia in 2020-21⁵³ and the UK in 2021-22⁵⁴. The
287 inter-seasonal viral activities were perhaps related to the increased susceptibility in the
288 population due to the lack of exposure to RSV during the previous year in response to
289 COVID-19⁵⁵.

290

291 Monoclonal antibodies approved for prophylactic therapy provide immediate protection of
292 high-risk individuals particularly young children against RSV-associated severe infections^{7,13}.

293 Five monthly injections of palivizumab and a single dose of nirsevimab can substantially
294 reduce the risk of hospitalizations due to RSV in individuals receiving the therapy throughout
295 RSV seasons especially in temperate regions where RSV seasons would normally not be
296 longer than 5 months. The duration of protection provided by RSV vaccines has not been
297 fully determined although promising efficacy for short-term prevention from infections was
298 demonstrated in clinical trials⁵⁶⁻⁵⁸. The effectiveness of the abovementioned pharmaceutical
299 interventions for high-risk population is determined by the duration of protection of the
300 monoclonal antibodies and the vaccines, the timing of administration and RSV activities in
301 specific locations. Ideally these preventive measures should be administered before an RSV
302 season starts, and the protection can maintain throughout the season, likely during November
303 - April, and May - October in temperate regions of the NH and the SH, respectively.
304 However great challenges in implementing these efficacious interventions would be seen in
305 locations where there were irregular seasons particularly with prolonged viral circulations⁵⁹⁻
306⁶¹. Based on the reported seasonal patterns in locations from northern temperate regions in
307 this review, the Studies incorporating epidemiologic analysis on RSV seasonality into the
308 effectiveness and cost-effectiveness of these RSV preventive strategies are urgently needed⁶².
309
310 There are several limitations in this study. First, data of RSV seasonality that were published
311 and included in the review were skewed to high-income countries with well-established RSV
312 surveillance systems. These countries are largely in temperate regions where RSV circulation
313 might be different from the underrepresented middle- and low-income countries due to varied
314 population structure, contact patterns and geoclimatic features⁶³. Second, RSV antigenic
315 information could not be incorporated into the current analysis of seasonality due to the lack
316 of data. Expanding RSV surveillance by collecting antigenic and genetic data is urgently
317 needed to improve our understanding of the transmission dynamics of RSV locally and

318 globally ⁶⁴. Third, except for the analytic method, we could not examine potential
319 associations between RSV seasonality and other study characteristics such as case sources,
320 case definitions, and laboratory methods due to the lack of information and non-standardized
321 laboratory protocols used for RSV surveillance, or explore the association between RSV
322 seasonality and population structure particularly birth rate given the lack of data although a
323 high disease burden of RSV identified in young children ⁶⁵⁻⁶⁷ implied a possible driving force
324 from the young population on RSV activities. Lastly, the reported data of seasonality in this
325 review did not allow us to investigate the RSV-associated disease burden occurred during the
326 characterised RSV seasons which is a critical metric for evaluation of the health impact
327 related to RSV circulation, particularly when there were large uncertainties in the start and
328 the end of RSV seasons in a specific location and the infection risk is less likely to be
329 homogeneous in a population over the season.

330

331 **CONCLUSIONS**

332 This study provided a global overview of RSV seasonality before the COVID-19 pandemic.
333 The seasonal patterns illustrated in this review may inform optimal use of preventive and
334 therapeutic interventions against RSV infection particularly in temperate regions of the NH
335 and SH. Considerable variations in methods used by different studies highlighted the
336 importance of developing and applying standardized approaches in RSV surveillance and
337 data reporting. Further research is needed to understand the underlying mechanisms driving
338 RSV seasonal patterns locally and globally.

339

340

341 **ACKNOWLEDGEMENTS**

342 The authors thank Prof. Julian W Tang, and Dr. Eeva Broberg for kindly sharing the data of
343 RSV seasonality from their publications. The authors also thank Stella SW Lai for technical
344 assistance.

345

346 **FUNDING**

347 This project was supported by the Health and Medical Research Fund (project no. 19200861)
348 from Food Bureau of Hong Kong SAR Government, and the AIR@InnoHK administered by
349 the Innovation and Technology Commission of Hong Kong SAR Government. The funding
350 bodies had no role in study design, data collection and analysis, preparation of the manuscript,
351 or the decision to publish.

352

353 **AUTHOR CONTRIBUTIONS**

354 All authors meet the International Committee of Medical Journal Editors criteria for
355 authorship. SS, PW, BY, DZ conceived and designed the study; SS, WZ, HG, PH collected
356 and extracted data; SS, PW conducted the data analysis and wrote the first draft of the
357 manuscript. All authors contributed to the interpretation of the results and revision of the
358 manuscript, and have approved the final version of the manuscript.

359

360 **DECLARATION OF INTERESTS**

361 JN was previously employed by and owns shares in Sanofi. The authors report no other
362 potential conflicts of interest.

363

364 **REFERENCES**

365

- 366 1. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of
367 acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in
368 2019: a systematic analysis. *Lancet* 2022; **399**(10340): 2047-64.
- 369 2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due
370 to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet* 2010;
371 **375**(9725): 1545-55.
- 372 3. Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in
373 acute lower respiratory infections in children under five years: A systematic review and meta-analysis.
374 *J Glob Health* 2015; **5**(1): 122-31.
- 375 4. Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory
376 viral infections in older adults with moderate to severe influenza-like illness. *J Infect Dis* 2014;
377 **209**(12): 1873-81.
- 378 5. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. *Drugs Aging*
379 2005; **22**(7): 577-87.
- 380 6. Troeger C, Forouzanfar M, Rao PC, et al. Estimates of the global, regional, and national
381 morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a
382 systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect Dis* 2017; **17**(11):
383 1133-61.
- 384 7. Brady MT, Byington CL, Davies HD, et al. Updated Guidance for Palivizumab Prophylaxis
385 Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial
386 Virus Infection. *Pediatrics* 2014; **134**(2): E620-E38.
- 387 8. Reeves RM, van Wijhe M, Lehtonen T, et al. A Systematic Review of European Clinical
388 Practice Guidelines for Respiratory Syncytial Virus Prophylaxis. *J Infect Dis* 2022; **226**(Suppl 1):
389 S110-S6.
- 390 9. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-
391 Preterm and Term Infants. *N Engl J Med* 2022; **386**(9): 837-46.

- 392 10. Simoes EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory
393 syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic
394 extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of
395 randomised controlled trials. *Lancet Child Adolesc Health* 2023; **7**(3): 180-9.
- 396 11. Garegnani L, Styrnisdottir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco
397 JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
398 *Cochrane Database Syst Rev* 2021; **11**(11): CD013757.
- 399 12. Null D, Bimle C, Weisman L, et al. Palivizumab, a humanized respiratory syncytial virus
400 monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk
401 infants. *Pediatrics* 1998; **102**(3): 531-7.
- 402 13. Keam SJ. Nirsevimab: First Approval. *Drugs* 2023; **83**(2): 181-7.
- 403 14. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach:
404 the vaccine and monoclonal antibody landscape. *Lancet Infect Dis* 2023; **23**(1): E2-E21.
- 405 15. Valero MV. Green light from US regulatory agency for GSK's jab caps off a decades-long
406 quest. 2023. <https://www.nature.com/articles/d41586-023-01529-5> (accessed May 6 2023).
- 407 16. Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus,
408 respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. *Lancet*
409 *Glob Health* 2019; **7**(8): e1031-e45.
- 410 17. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory Syncytial Virus
411 Seasonality: A Global Overview. *J Infect Dis* 2018; **217**(9): 1356-64.
- 412 18. Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P, European Influenza Surveillance
413 N. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European
414 countries, 2010 to 2016. *Euro Surveill* 2018; **23**(5).
- 415 19. Staadegaard L, Caini S, Wangchuk S, et al. Defining the seasonality of respiratory syncytial
416 virus around the world: National and subnational surveillance data from 12 countries. *Influenza Other*
417 *Respir Viruses* 2021; **15**(6): 732-41.
- 418 20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and
419 meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015; **4**(1): 1.

- 420 21. Geocoding API. <https://developers.google.com/maps/documentation/geocoding>.
- 421 22. GSODR: Global Surface Summary of the Day ('GSOD') Weather Data Client. [https://cran.r-](https://cran.r-project.org/web/packages/GSODR/index.html)
422 [project.org/web/packages/GSODR/index.html](https://cran.r-project.org/web/packages/GSODR/index.html).
- 423 23. Khor CS, Sam IC, Hooi PS, Quek KF, Chan YF. Epidemiology and seasonality of respiratory
424 viral infections in hospitalized children in Kuala Lumpur, Malaysia: a retrospective study of 27 years.
425 *Bmc Pediatr* 2012; **12**.
- 426 24. Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. *Clin Microbiol*
427 *Rev* 2000; **13**(1): 1-15, table of contents.
- 428 25. Bhattacharyya S, Gesteland PH, Korgenski K, Bjornstad ON, Adler FR. Cross-immunity
429 between strains explains the dynamical pattern of paramyxoviruses. *P Natl Acad Sci USA* 2015;
430 **112**(43): 13396-400.
- 431 26. White LJ, Waris M, Cane PA, Nokes DJ, Medley GF. The transmission dynamics of groups
432 A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and
433 cross-protection. *Epidemiol Infect* 2005; **133**(2): 279-89.
- 434 27. Chadha M, Hirve S, Bancej C, et al. Human respiratory syncytial virus and influenza
435 seasonality patterns-Early findings from the WHO global respiratory syncytial virus surveillance.
436 *Influenza Other Resp* 2020; **14**(6): 638-46.
- 437 28. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection
438 in young children. *N Engl J Med* 2009; **360**(6): 588-98.
- 439 29. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection.
440 *Pediatr Infect Dis J* 2003; **22**(2): S40-S5.
- 441 30. Hogan AB, Glass K, Moore HC, Anderssen RS. Exploring the dynamics of respiratory
442 syncytial virus (RSV) transmission in children. *Theor Popul Biol* 2016; **110**: 78-85.
- 443 31. Savic M, Penders Y, Shi T, Branche A, Pircon JY. Respiratory syncytial virus disease burden
444 in adults aged 60 years and older in high-income countries: A systematic literature review and meta-
445 analysis. *Influenza Other Resp* 2023; **17**(1).

- 446 32. Shi T, Denouel A, Tietjen AK, et al. Global Disease Burden Estimates of Respiratory
447 Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic
448 Review and Meta-Analysis. *J Infect Dis* 2020; **222**: S577-S83.
- 449 33. Leung NHL. Transmissibility and transmission of respiratory viruses. *Nat Rev Microbiol*
450 2021; **19**(8): 528-45.
- 451 34. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. *Annu*
452 *Rev Virol* 2020; **7**: 83-101.
- 453 35. Paynter S. Humidity and respiratory virus transmission in tropical and temperate settings.
454 *Epidemiol Infect* 2015; **143**(6): 1110-8.
- 455 36. Tang JLW, Loh TP. Correlations between climate factors and incidence-a contributor to RSV
456 seasonality. *Rev Med Virol* 2014; **24**(1): 15-34.
- 457 37. Hampp C, Asal N, Lipowski E, et al. Validity of Laboratory-based Surveillance for Detection
458 of Respiratory Syncytial Virus Seasons. *Am J Epidemiol* 2013; **177**(8): 841-51.
- 459 38. Ambrose CS, Steed LL, Brandon M, Frye K, Olajide IR, Thomson G. National and regional
460 modeling of distinct RSV seasonality thresholds for antigen and PCR testing in the United States. *J*
461 *Clin Virol* 2019; **120**: 68-77.
- 462 39. Midgley CM, Haynes AK, Baumgardner JL, et al. Determining the Seasonality of Respiratory
463 Syncytial Virus in the United States: The Impact of Increased Molecular Testing. *J Infect Dis* 2017;
464 **216**(3): 345-55.
- 465 40. Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory Syncytial Virus
466 Seasonality - United States, 2014-2017. *Mmwr-Morbid Mortal W* 2018; **67**(2): 71-6.
- 467 41. National Respiratory and Enteric Virus Surveillance System.
468 <https://www.cdc.gov/surveillance/nrevss/index.html>.
- 469 42. Flu (influenza): FluWatch surveillance - Canada.ca. [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance.html)
470 [health/services/diseases/flu-influenza/influenza-surveillance.html](https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance.html).
- 471 43. Surveillance Atlas of Infectious Diseases. <https://atlas.ecdc.europa.eu/public/index.aspx>.

- 472 44. Broor S, Campbell H, Hirve S, et al. Leveraging the Global Influenza Surveillance and
473 Response System for global respiratory syncytial virus surveillance-opportunities and challenges.
474 *Influenza Other Resp* 2020; **14**(6): 622-9.
- 475 45. Hirve S, Crawford N, Palekar R, Zhang WQ, Grp WRS. Clinical characteristics, predictors,
476 and performance of case definition-Interim results from the WHO global respiratory syncytial virus
477 surveillance pilot. *Influenza Other Resp* 2020; **14**(6): 647-57.
- 478 46. Teirlinck AC, Broberg EK, Berg AS, et al. Recommendations for respiratory syncytial virus
479 surveillance at the national level. *Eur Respir J* 2021; **58**(3).
- 480 47. Mollers M, Barnadas C, Broberg EK, et al. Current practices for respiratory syncytial virus
481 surveillance across the EU/EEA Member States, 2017. *Euro Surveill* 2019; **24**(40).
- 482 48. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-
483 19 nonpharmaceutical interventions on the future dynamics of endemic infections. *Proc Natl Acad Sci*
484 *U S A* 2020; **117**(48): 30547-53.
- 485 49. Oh DY, Buda S, Biere B, et al. Trends in respiratory virus circulation following COVID-19-
486 targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of
487 national surveillance data. *Lancet Reg Health Eur* 2021; **6**: 100112.
- 488 50. Bozzola E, Barni S, Villani A. Respiratory Syncytial Virus Pediatric Hospitalization in the
489 COVID-19 Era. *Int J Environ Res Public Health* 2022; **19**(23).
- 490 51. Fairbank R. RSV wave hammers hospitals - but vaccines and treatments are coming. *Nature*
491 2022.
- 492 52. Lindsey Wang PBD, Nathan A Berger, David C Kaelber, Nora D Volkow, Rong Xu.
493 Disruption in seasonality, patient characteristics and disparities of respiratory syncytial virus infection
494 among young children in the US during and before the COVID-19 pandemic: 2010-2022. medRxiv;
495 2022.
- 496 53. Eden JS, Sikazwe C, Xie RP, et al. Off-season RSV epidemics in Australia after easing of
497 COVID-19 restrictions. *Nat Commun* 2022; **13**(1).
- 498 54. Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial virus in
499 children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory,

- 500 clinical, and syndromic surveillance: a retrospective observational study. *Lancet Infect Dis* 2023;
501 **23**(1): 56-66.
- 502 55. Garg I, Shekhar R, Sheikh A, Pal S. Impact of COVID-19 on the Changing Patterns of
503 Respiratory Syncytial Virus Infections. *Infect Dis Rep* 2022; **14**(4): 558-68.
- 504 56. Falsey AR, Williams K, Gymnopoulou E, et al. Efficacy and Safety of an Ad26.RSV.preF-
505 RSV preF Protein Vaccine in Older Adults. *N Engl J Med* 2023; **388**(7): 609-20.
- 506 57. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to
507 Prevent RSV Illness in Infants. *N Engl J Med* 2023; **388**(16): 1451-64.
- 508 58. Walsh EE, Perez Marc G, Zareba AM, et al. Efficacy and Safety of a Bivalent RSV Prefusion
509 F Vaccine in Older Adults. *N Engl J Med* 2023; **388**(16): 1465-77.
- 510 59. Bauman J, Eggleston M, Oquist N, Malinoski F. Respiratory syncytial virus: Seasonal data
511 for regions of Florida and implications for palivizumab. *South Med J* 2007; **100**(7): 669-76.
- 512 60. Hsu CH, Lin CY, Chi H, et al. Prolonged Seasonality of Respiratory Syncytial Virus Infection
513 among Preterm Infants in a Subtropical Climate. *Plos One* 2014; **9**(10).
- 514 61. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on
515 prevention strategies. *Hum Vacc Immunother* 2018; **14**(1): 234-44.
- 516 62. Getaneh AM, Li X, Mao Z, et al. Cost-effectiveness of monoclonal antibody and maternal
517 immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European
518 countries. *Vaccine* 2023; **41**(9): 1623-31.
- 519 63. Tang JW, Lam TT, Zaraket H, et al. Global epidemiology of non-influenza RNA respiratory
520 viruses: data gaps and a growing need for surveillance. *Lancet Infect Dis* 2017; **17**(10): E320-E6.
- 521 64. Staadegaard L, Meijer A, Rodrigues AP, et al. Temporal Variations in Respiratory Syncytial
522 Virus Epidemics, by Virus Subtype, 4 Countries. *Emerg Infect Dis* 2021; **27**(5): 1537-40.
- 523 65. Glatman-Freedman A, Kaufman Z, Applbaum Y, et al. Respiratory Syncytial Virus
524 hospitalization burden: a nation-wide population-based analysis, 2000-2017. *J Infect* 2020; **81**(2):
525 297-303.

- 526 66. Johannesen CK, van Wijhe M, Tong S, et al. Age-Specific Estimates of Respiratory Syncytial
527 Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis. *J Infect Dis*
528 2022; **226**(Suppl 1): S29-S37.
- 529 67. Tong S, Amand C, Kieffer A, Kyaw MH. Incidence of respiratory syncytial virus related
530 health care utilization in the United States. *J Glob Health* 2020; **10**(2): 020422.
- 531

532 **Table 1. Characteristics of publications and investigations included in the systematic**
 533 **review.**

Characteristics	No. of Publications (N=209)^a n (%)	No. of Investigations (N = 552) n (%)
Climatic zone		
Temperate (>35°)	123 (58.9)	335 (60.7)
Subtropical (23.5° - 35°)	65 (31.1)	134 (24.3)
Tropical (equator - 23.5°)	49 (23.4)	83 (15.0)
Continent		
Asia	64 (30.6)	140 (25.4)
Europe	68 (32.5)	155 (28.1)
North America	38 (18.2)	164 (29.7)
South America	14 (6.7)	49 (8.9)
Africa	12 (5.7)	24 (4.3)
Oceania	5 (2.4)	19 (3.4)
Others ^b	8 (3.8)	1 (0.2)
Study period^c		
Before Palivizumab approved	88 (42.1)	147 (26.6)
After Palivizumab approved	75 (35.9)	320 (58.0)
Others ^d	46 (22.0)	85 (15.4)
Length of study period		
3-6 years	127 (60.8)	342 (62.0)
7-10 years	53 (25.4)	123 (22.3)
> 10 years	37 (17.7)	87 (15.8)
Type of RSV data		
Weekly data	57 (27.3)	294 (53.3)
Monthly data	155 (74.2)	258 (46.7)
Analytic method		
Qualitative	146 (69.9)	179 (32.4)
Quantitative	66 (31.6)	373 (67.6)

Threshold-based	54 (25·9)	205 (37·1)
Coverage-based	8 (3·8)	142 (25·7)
Model-based	6 (2·9)	26 (4·7)
RSV case source		
Inpatient	94 (45·0)	152 (27·5)
Outpatient	14 (6·7)	25 (4·5)
Both	53 (25·4)	115 (20·8)
Unknown	48 (23·0)	260 (47·1)
RSV case definition ^e		
ARI or ILI	82 (39·2)	150 (27·2)
SARI	23 (11·0)	45 (8·2)
ALRI	48 (23·0)	59 (10·7)
Clinical judgement	9 (4·3)	30 (5·4)
Unknown	70 (33·5)	310 (56·2)
Testing method ^f		
Virus detection	45 (21·5)	168 (30·4)
Antigen detection	107 (51·2)	303 (54·9)
Antibody detection	8 (3·8)	42 (7·6)
Nucleic acid detection	110 (52·6)	323 (58·5)
Unknown	33 (15·8)	127 (23·0)

534 Note: ARI, acute respiratory infection; ILI, influenza-like illness; SARI, severe acute respiratory infection;
535 ALRI, acute lower respiratory infection

536 ^aAn investigation was identified as an analysis with a specified method on the reported RSV data for the
537 seasonality of RSV activities. Analyses on the same data with different analytic methods were recognized as
538 different investigations. A publication might include several investigations describing the seasonality of RSV
539 activities by analysing different sets of data, or applying different analytic methods, etc. Therefore, the sum of
540 investigations might be greater than the total number of publications.

541 ^bRefers to the publications/investigations with study sites involving more than one continent.

542 ^c For different locations, the time for palivizumab to be licensed for prophylactic use are different. For the
543 countries where palivizumab has not been licensed, such as China, all the publications/investigations of this
544 country would be recognized as “before palivizumab approved”.

545 ^d Refers to the publications/investigations in which the study period contains the periods both before and after
546 the year when Palivizumab was approved in the study locations.

547 ^e A publication/investigation on RSV seasonality might be based on multiple sources of cases, e.g., ARI, ILI and
548 SARI perhaps were used together or in different combinations to identify patients for RSV testing. Some
549 investigations/studies might be counted multiple times, and the sum of the proportions of
550 publications/investigations from different case definition categories may exceed 100%.

551 ^f A publication/investigation on RSV seasonality might adopt multiple testing methods for RSV detection. Some
552 investigations/studies might be counted multiple times, and the sum of the proportions of
553 publications/investigations from different testing method categories may exceed 100%.

554 **Table 2. Associations identified in the linear regression analysis between durations of**
 555 **RSV seasons estimated from quantitative approaches and characteristics of the studies.**
 556

Variable	Change in duration of RSV season (months)	95% confidence interval	p-value
Climatic zone			
Temperate region (<-35° or >35°)	0	Referent	
Subtropical region (-35° - -23.5° or 23.5° - 35°)	1.06	0.45, 1.66	<0.001
Tropical region (-23.5° - 23.5°)	1.65	0.77, 2.54	<0.001
Analysis method			
Coverage-based method	0	Referent	
Threshold-based method	1.43	0.96, 1.90	<0.001
Model-based method	1.98	-0.99, 4.95	0.19
Meteorological factor			
Daily average mean absolute humidity	0.013	-0.0049, 0.030	0.15


557


558 **FIGURE LEGENDS**

559 **Figure 1. Flowchart of study identification and selection for the systematic review.**

560 **Figure 2. Geographic distribution of study locations and the reported RSV seasonal**
561 **patterns from all included investigations using either quantitative or qualitative**
562 **approaches.**

563 **Figure 3. The timing of one-peak RSV seasons reported in investigations using either**
564 **quantitative or qualitative approaches against the latitude of the study site located in**
565 **the Northern Hemisphere (NH, centred at the north pole) in panels A, C and E, and**
566 **Southern Hemisphere (SH, centred at the south pole) in panels B, D and F. The start (A),**
567 **peak (C) and end (E) of RSV seasons in NH. The start (B), peak (D) and end (F) of RSV**
568 **seasons in SH. The centre of the radius circles represents the north pole or the south pole**
569 **(latitude = 90°) and the external border represents the equator (latitude = 0°). The circles**
570 **were divided by the dashed radiuses into 12 sections to represent 12 months of a year. Two**
571 **radius circles between the north/south pole and the external border indicating the latitudes at**
572 **23.5° and 35° are used to define the temperate region (35°-90°), subtropical region (23.5°-35°)**
573 **and tropical region (equator-23.5°).**






Northern Hemisphere


A.

Month of season start



Southern Hemisphere


B.




C.

Month of season peak

medRxiv preprint doi: <https://doi.org/10.1101/2023.06.12.23291266>; this version posted June 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).




D.



E.

Month of season end



F.

